Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.6171
+0.0541 (9.61%)
At close: Sep 26, 2025, 4:00 PM EDT
0.6349
+0.0178 (2.88%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Plus Therapeutics Employees
Plus Therapeutics had 21 employees as of December 31, 2024. The number of employees increased by 1 or 5.00% compared to the previous year.
Employees
21
Change (1Y)
1
Growth (1Y)
5.00%
Revenue / Employee
$253,190
Profits / Employee
-$906,048
Market Cap
61.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21 | 1 | 5.00% |
| Dec 31, 2023 | 20 | 3 | 17.65% |
| Dec 31, 2022 | 17 | 3 | 21.43% |
| Dec 31, 2021 | 14 | 2 | 16.67% |
| Dec 31, 2020 | 12 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PSTV News
- 2 days ago - Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - GlobeNewsWire
- 5 days ago - Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT - GlobeNewsWire
- 9 days ago - Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory - GlobeNewsWire
- 25 days ago - Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights - GlobeNewsWire